{"name":"King Abdullah International Medical Research Center","slug":"king-abdullah-international-medical-research-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Leukotriene Receptor Antagonist","genericName":"Leukotriene Receptor Antagonist","slug":"leukotriene-receptor-antagonist","indication":"Asthma (persistent mild to moderate)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Nilotinib 300 mg.","genericName":"Nilotinib 300 mg.","slug":"nilotinib-300-mg","indication":"Chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Nucleos(t)tide analogues","genericName":"Nucleos(t)tide analogues","slug":"nucleos-t-tide-analogues","indication":"Chronic hepatitis B infection","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"low-dose epinephrine and tranexamic acid","genericName":"low-dose epinephrine and tranexamic acid","slug":"low-dose-epinephrine-and-tranexamic-acid","indication":"Acute hemorrhage and hemorrhagic shock","status":"marketed"}]}],"pipeline":[{"name":"Leukotriene Receptor Antagonist","genericName":"Leukotriene Receptor Antagonist","slug":"leukotriene-receptor-antagonist","phase":"phase_3","mechanism":"Leukotriene receptor antagonists block cysteinyl leukotriene receptors on airway and immune cells, reducing inflammatory mediator signaling.","indications":["Asthma (persistent mild to moderate)","Allergic rhinitis","Exercise-induced bronchoconstriction"],"catalyst":""},{"name":"Nilotinib 300 mg.","genericName":"Nilotinib 300 mg.","slug":"nilotinib-300-mg","phase":"marketed","mechanism":"Nilotinib is a tyrosine kinase inhibitor that selectively blocks BCR-ABL and other kinases to inhibit abnormal cell proliferation in chronic myeloid leukemia.","indications":["Chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis","Philadelphia chromosome-positive acute lymphoblastic leukemia"],"catalyst":""},{"name":"Nucleos(t)tide analogues","genericName":"Nucleos(t)tide analogues","slug":"nucleos-t-tide-analogues","phase":"marketed","mechanism":"Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase enzymes, preventing viral nucleic acid synthesis and replication.","indications":["Chronic hepatitis B infection","HIV infection","Chronic hepatitis C infection (select agents)"],"catalyst":""},{"name":"low-dose epinephrine and tranexamic acid","genericName":"low-dose epinephrine and tranexamic acid","slug":"low-dose-epinephrine-and-tranexamic-acid","phase":"marketed","mechanism":"Low-dose epinephrine stimulates adrenergic receptors to increase heart rate and blood pressure, while tranexamic acid inhibits fibrinolysis to reduce bleeding.","indications":["Acute hemorrhage and hemorrhagic shock","Trauma-related bleeding"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOZGswWWVJYmJ5Ukl6R2NkdXpwSTdTam1DMXI4TVE1LU1NWjRrVmNuNXJtZkVfclNJeFFGVXQ1OE0tdXJQQkttcGwwSDhrVzl3MEhTenV6X2lGdm1nU2dhOXBhWHZxSldUR0kwaDlOZGhzRTFyRUQtRGRYTHMyWTFaeTcyOVpJdGk3d0FTZ3owUlFGd2RDcE8xaU56R3VoUVRwbGh6VE9rdy1SM003Zkx1ZGd6WmVBZjlCcEE?oc=5","date":"2026-01-16","type":"pipeline","source":"CRISPR Medicine News","summary":"Guest post: Beyond the R&D Pharma Walls: Safari visit of Middle Eastern and African Researchers - CRISPR Medicine News","headline":"Guest post: Beyond the R&D Pharma Walls: Safari visit of Middle Eastern and African Researchers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNdlRyalM5bUNWNDNqb1QxWUo0aGxiOEtlUXQ5OEdaOHU4MDBLYllaUk82RW9oRW9ocmx3R01JTVNLZ1VyOGMtcFM3a1l3YU9sQ05Ccl90Qmk4bWI1eHRiWllSX3lydmo2czF1TjUwM0pwMEs1M3pGV0U4dEtacmUzYWRRVW1FTTh6Sm5JaS1JMXRJcTBjRlBEclo1azB4d3BrV1ZRU2c0LUhSYy02N0VPYTh4bjdwaXNOVkJncEFuWV9qcGNxNmtZZHdsOG1qcXlhdGRldkg4RldWNG0yS0hGbW14NlUwOG9jci1jSUZPSjF6NUlmQlFzWlN0V0I0LWpWa1A1VWh3VEdQS3Rnc1Jlek83b1dWWFh2cHhZUVJnRmx6a2dZYmhCVkJtc0NEMzUtZnRNQmxmWTZiMW1PXzktaGVPcldBR09s?oc=5","date":"2025-11-19","type":"deal","source":"prnewswire.com","summary":"King Abdullah International Medical Research Center and Flagship Pioneering Announce Strategic Partnership to Expand Clinical Research of Novel Medicines in Saudi Arabia - prnewswire.com","headline":"King Abdullah International Medical Research Center and Flagship Pioneering Announce Strategic Partnership to Expand Cli","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPN1NkYVo2Yi1yd1JzaXRjZ0NzSzRzZTc1Z3hMTndTZjMyODJSWUVtbDNlUWJNU1F0VC1tdnBFUnJIeURzdmhqZkpncmpkM0ZGZHA1TEhCa056dVBvem9rSnU2MGZpYlJqd3g0ay1hSkVhX3FwNGxab0cycFdfU3YxU1dqTGp2VS04UHZGYmxmd2I0QXdGeVhRLU5xSmM?oc=5","date":"2025-10-29","type":"pipeline","source":"Frontiers","summary":"Genomics-Driven Drug Repurposing and Novel Targets Identification for Sickle Cell Disease in Saudi Patients - Frontiers","headline":"Genomics-Driven Drug Repurposing and Novel Targets Identification for Sickle Cell Disease in Saudi Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPRllSYWxhRzF1ZnNRYWJqNk0zbXhGMndtNk01UjRuUWJfUEhlQS1fVFQ2b2g1VzF5aWFsanpvUlFEWGs0ZWx4ZExudll2b2lSNkFjNG5kUXNCVWc2M21FYjA1b016V0hoVXl6cFRnQU9uS0FiMnRXN3ZzSmVwa0NseE1LYXBfVTEyZWc?oc=5","date":"2025-10-13","type":"pipeline","source":"Fortune Business Insights","summary":"Saudi Arabia Pharmaceuticals Market Size, Share [2032] - Fortune Business Insights","headline":"Saudi Arabia Pharmaceuticals Market Size, Share [2032]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE05QUhhSU9NcFgyU2hfenVMMWFxMG5IYm1RQ1Z6V2RvcjdRRVFUZzAxN09qeEpKRHh2bk9Nd1VsUW5uaXZNaFo0RmoyblRKUUtQb1o0?oc=5","date":"2025-09-02","type":"deal","source":"Arab News","summary":"Saudi Arabia, UAE dominate healthcare deals in GCC, JLL says - Arab News","headline":"Saudi Arabia, UAE dominate healthcare deals in GCC, JLL says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQMmxUUllfeXVueVBYaXh0dUUzTFJiYjB2cGk0LWszbzlCSUk0U2NUaXF0Wm9XUmRPVWxvZnJxMk1aT1djSEU0U25wNE5DV0NJV0JlZjl2dEZUbGozalZUVDNMYU9sa0V2LUxQUlI1b0hRUkp1dEhDa3RyZ1IzQ1RLQXFlUm5nRUVzZVJvTEhwUFVMOFBBb09ZcXFyUUhnTE9FMmNzcWR5TUgtalo0cTE3X3RsV2NDQUx1cmhTMkF0c2FkUkUxYW45SmFhcjVtZ0k1eFlhMlBpazh2NHBMX3gwWTZKYkg2RkUyUDg4V1VXc0w?oc=5","date":"2025-06-17","type":"deal","source":"GlobeNewswire","summary":"Saudi Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025 - GlobeNewswire","headline":"Saudi Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQVjJLbE5vc1FQYW0yY1VBdGhja1JiWEFOZ3BjNmg3TTV4bDE0ZUxEQTZNX25jNVljR25MakY2UXlGbkluY29aNGFDblZzYzgtellDd29vcGlobkNWSzFTT2xIc1h0NFduZy13SEEzMDJuc09OdlZ3b210Ykd6OS15aTdKTk5NWHhGTlZaazVSazd2TFZsTjh4S3NxaC1BZzVnUEdYd2xZTEg1WnJsUnpQeXB6bzRVSHZFTjhzUW9EQVFNN09vNHpKOEY1bW8?oc=5","date":"2025-05-13","type":"pipeline","source":"Dove Medical Press","summary":"CPAA - Dove Medical Press","headline":"CPAA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE03cGZWSXQ3MjFkd01xT1U4aUF6aGhkU212Yk1SenRoelF1VUVGbUM4ZnZycjZ5NENlMGU3Ulg5YjJFbUlzaXctZHlSU3NnOFY5WkNMNXhUYnRnTlZTeDZtWXI3TzJTeEc3cVJv?oc=5","date":"2025-01-09","type":"pipeline","source":"Labiotech.eu","summary":"Saudi Arabia: is the country set to become a global biotech hub? - Labiotech.eu","headline":"Saudi Arabia: is the country set to become a global biotech hub?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-11-27","type":"trial","source":"Business Wire","summary":"AI Startup, Recursive, Signs Memorandum of Understanding with Saudi Arabia’s Largest Medical Research Institution, King Abdullah International Medical Research Center, to Develop AI and Data Science S","headline":"AI Startup, Recursive, Signs Memorandum of Understanding with Saudi Arabia’s Largest Medical Research Institution, King ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOYlFzNUJ6SkRDbmxXc1BLemJkeGVGN2FnemZSUHFvMmpUM3V2V25BU0tzaFA3X1dxVzVVOWtLTG5MUzA0UU9zWkJSVEJPcE1yMmZnLS0xYk4xdl9ZclJiOHVQeFRyMjVkYUJkdWRjUW40Mkd5c1k3OUhxTVJSQWlxU2NzS2xhOUlVNDVUaDNMR0ZvcjRfNnBUUVVTcENwUU9LeEF2YmVJWUItM0hYUWVXS21TYktZVWhvYnI0RWxqOUhJZ3F1Tkd1dm5YMGs2RDg2ZEhHS2JYaWc?oc=5","date":"2024-08-01","type":"pipeline","source":"BioSpace","summary":"Saudi Arabia Pharmaceuticals Market Size to Reach USD 11.5 Billion by 2032, Impelled by Rising Healthcare Expenditure - BioSpace","headline":"Saudi Arabia Pharmaceuticals Market Size to Reach USD 11.5 Billion by 2032, Impelled by Rising Healthcare Expenditure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9aZmlTWnJHMUlGb25Zd2xpSnRCei05UXdIVTNKc1hpZXdVUkVhTVZXelZHRnpFN1pQQUprMUEwR3JOT0JZZHl6S2NERTNwUE5tdjhWcjl3c2hSQmpxdENj?oc=5","date":"2022-05-24","type":"pipeline","source":"Nature","summary":"A global effort - Nature","headline":"A global effort","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBmZ1h0ckV0QmE0UjRsTnlXdTgyLTZvc0NUM2htamJlVHljZ0pZSW9VS01qZE9NcUZCSzNIMy14Q0Z3b211ZndrcXNmeWVib0czdGE2SkhwM2ZQQy03a2dF?oc=5","date":"2020-02-28","type":"pipeline","source":"Nature","summary":"Revolutionizing the clinical research landscape in Saudi Arabia - Nature","headline":"Revolutionizing the clinical research landscape in Saudi Arabia","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"marketed":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}